Ropes & Gray advised ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a clinical collaboration with Gilead Sciences to evaluate the safety and anti-leukemia activity of ImmunoGen’s ADC, pivekimab sunirine, in combination with Gilead’s drug magrolimab, a potential first-in-class investigational inhibitor for patients with relapsed or refractory positive acute myeloid leukemia blood cancer. The clinical collaboration was announced on December 9. Financial terms were not disclosed.
Expected to initiate in 2023, the collaboration will create a new cohort in ImmunoGen’s “802 study,” a Phase 1b/2 clinical trial to evaluate pivekimab in combination with magrolimab in patients with positive AML.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and included health care partner David Peloquin and corporate associate Mike Tentilucci.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
